Actions

Difference between revisions of "SFI Medical Short Course 2016 - Interest Group Meetings 2016"

From Santa Fe Institute Events Wiki

Line 13: Line 13:
  
  
==A network theory approach to diagnostic pathways==
+
==Interest Group 1: A network theory approach to diagnostic pathways==
 
Interested: Bob Wolber, Patricia Wang, Ethan Davenport <br>
 
Interested: Bob Wolber, Patricia Wang, Ethan Davenport <br>
  
Line 19: Line 19:
 
Interested: Bob Wolber, Seth Starner, Bryan Ressler, Murray Feldstein  <br>
 
Interested: Bob Wolber, Seth Starner, Bryan Ressler, Murray Feldstein  <br>
  
==Orphan Treatments==
+
==Interest Group 2: Orphan Treatments==
 
Getting medical research into medical practice is fraught with obstacles - not just scientific and medical but also financial, regulatory, administrative, social, and cultural. These “valleys of death” mean that patients do not receive treatments that are actually known to be effective, but may become orphan drugs, devices or practices. And yet in our society real orphans can survive, given foster parents or adoptive parents, to become self-supporting and productive members of our ecosystem. Why not orphan treatments? The health care system is complex, and getting new treatments into practice requires some understanding of this complexity.
 
Getting medical research into medical practice is fraught with obstacles - not just scientific and medical but also financial, regulatory, administrative, social, and cultural. These “valleys of death” mean that patients do not receive treatments that are actually known to be effective, but may become orphan drugs, devices or practices. And yet in our society real orphans can survive, given foster parents or adoptive parents, to become self-supporting and productive members of our ecosystem. Why not orphan treatments? The health care system is complex, and getting new treatments into practice requires some understanding of this complexity.
  
 
Interested: Graham Creasey<br>
 
Interested: Graham Creasey<br>
  
==Complex systems approach to understanding human aging==
+
==Interest Group 3: Complex systems approach to understanding human aging==
 
Interested: Heather E. Whitson, Bryan Ressler<br>
 
Interested: Heather E. Whitson, Bryan Ressler<br>
  
==Understanding and managing complexity in health care quality improvement==
+
==Interest Group 4: Understanding and managing complexity in health care quality improvement==
 
Interested: Meghan Lane-Fall, Aaron Miller, and Andy Valenciano<br>
 
Interested: Meghan Lane-Fall, Aaron Miller, and Andy Valenciano<br>
  
==Grantsmanship and strategies to obtain research funding for complexity-based research in medicine, whether it be clinical, basic science, or translational research.==
+
==Interest Group 5: Grantsmanship and strategies to obtain research funding for complexity-based research in medicine, whether it be clinical, basic science, or translational research.==
 
Interested: Elizabeth Lusczek<br>
 
Interested: Elizabeth Lusczek<br>

Revision as of 15:48, 13 October 2016

Education Event Navigation

{border}


We will be holding interest group meetings during the course, these can manifest in two ways:

1. You can meet with a small group to discuss a specific topic, email education@santafe.edu with potential topics for discussion groups and to sign up for topics
2. Or you can use this time to have an in-depth one-on-one meeting with a participant that is of interest to you (I will distribute a participant list)

Please submit interest group topics before 1pm on the 13th. We will post sign up sheets over the afternoon break on the 13th.

Interest Group Meetings

Interest Group 1: A network theory approach to diagnostic pathways

Interested: Bob Wolber, Patricia Wang, Ethan Davenport

Proficiency testing as a genetic algorithm

Interested: Bob Wolber, Seth Starner, Bryan Ressler, Murray Feldstein

Interest Group 2: Orphan Treatments

Getting medical research into medical practice is fraught with obstacles - not just scientific and medical but also financial, regulatory, administrative, social, and cultural. These “valleys of death” mean that patients do not receive treatments that are actually known to be effective, but may become orphan drugs, devices or practices. And yet in our society real orphans can survive, given foster parents or adoptive parents, to become self-supporting and productive members of our ecosystem. Why not orphan treatments? The health care system is complex, and getting new treatments into practice requires some understanding of this complexity.

Interested: Graham Creasey

Interest Group 3: Complex systems approach to understanding human aging

Interested: Heather E. Whitson, Bryan Ressler

Interest Group 4: Understanding and managing complexity in health care quality improvement

Interested: Meghan Lane-Fall, Aaron Miller, and Andy Valenciano

Interest Group 5: Grantsmanship and strategies to obtain research funding for complexity-based research in medicine, whether it be clinical, basic science, or translational research.

Interested: Elizabeth Lusczek